Odimma Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Odimma Therapeutics - overview
Established
2017
Location
Strasbourg, -, France
Primary Industry
Biotechnology
About
Based in Strasbourg, France, and founded in 2017 by Jean-Marc Limacher, and Jessica Matta (CEO), Odimma Therapeutics operates as a biotechnology company specializing in personalized cancer immunotherapy and customized medicine. In April 2023, Odimma Therapeutics raised EUR 2 million in seed funding from Alsace Business Angels, Angels Santé, Bpifrance, Capital Grand Est, etc. Odimma Therapeutics has developed an immunotherapy drug that aims to enhance personalized cancer immunotherapy. By utilizing a platform that combines three immune players, this drug can work in synergy with the immune system to induce and amplify an immune response.
The firm empowers patients to effectively treat tumors with fewer side effects. In addition, the company's mission is to advance immunotherapy treatments and improve the lives of cancer patients. The company plans to use the April 2023 funding to further the development of its ODI-2001, personalized immunotherapy against cancer.
Current Investors
Capital Grand Est
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.odimma-therapeutics.com
Verticals
HealthTech, Manufacturing
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Odimma Therapeutics - financials
| Fiscal Year Ended | Dec 31, 2018 |
|---|---|
| Revenue (USD) | - |
| % Revenue Growth (YoY) | - |
| EBITDA (USD) | - |
| Operating Income (USD) | - |
| Operating Margin | - |
| % EBITDA Margin | - |
| NET Income (USD) | - |
| % Net Margin | - |
Odimma Therapeutics - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.